Search
Desirudin
go.drugbank.com/drugs/DB11095ApprovedWithdrawnIt has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis.
Talniflumate
go.drugbank.com/drugs/DB09295InvestigationalPhase I trials with talniflumate for the treatment of cystic fibrosis and COPD were completed in August 2001, and phase II trials were performed in Ireland for the treatment of cystic fibrosis but this
XTL-6865
go.drugbank.com/drugs/DB06058InvestigationalIt is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease. … XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein.
Ferrous asparto glycinate
go.drugbank.com/drugs/DB11169ApprovedFerrous asparto glycinate is an iron-amino acid chelate. It is available as a dietary supplement used in the treatment of iron deficiency and iron deficiency anemia.
Mixtures: UltimateCare ONE NFAT1391
go.drugbank.com/drugs/DB05120ExperimentalAT1391 is a daily insulin skin patch designed to provide continuous basal levels of insulin for patients with diabetes.
SC12267
go.drugbank.com/drugs/DB05125InvestigationalSC12267 is a novel, small molecule agent from the class of DMARDs (disease modifying anti-rheumatic drug) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis.
Opaganib
go.drugbank.com/drugs/DB12764InvestigationalOpaganib, also known as ABC294640, is a selective sphingosine kinase-2 (SK2) (https://go.drugbank.com/polypeptides/Q9NRA0) inhibitor that is orally administered. This drug has potential anticancer, anti-inflammatory, and antiviral activi...
SP1049C
go.drugbank.com/drugs/DB04978Experimental[A260416] It is designed to overcome drug resistance in a number of cancers. It has successfully completed Phase 1 trials. Phase 2 results are currently under final review. … SP1049C is a novel anthracycline chemotherapeutic agent containing [doxorubicin] and two nonionic pluronic block copolymers.
NLX-P101
go.drugbank.com/drugs/DB05924ExperimentalNLX-P101, gene therapy is developed by Neurologix to treat Parkinson’s disease. … NLX-P101 is being evaluated as a therapeutic drug when injected into this deep brain structure that is known to function abnormally in Parkinson’s patients.
Leukotriene C4
go.drugbank.com/drugs/DB08855Experimental(From Dictionary of Prostaglandins and Related Compounds, 1990)
Synonyms: (R-(R*,S*-(E,E,Z,Z)))-N-(S-(1-(4-Carboxy-1-hydroxybutyl)-2,4,6,9-pentadecatetraenyl)-N-L-gamma-glutamyl-L-cysteinyl)glycine, L-γ-glutamyl-S-[(1R,2E,4E,6Z,9Z)-1-[(1S)-4-carboxy-1-hydroxybutyl]pentadeca-2,4,6,9-tetraen-1-yl]-L-cysteinylglycine